X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (3847) 3847
Journal Article (2554) 2554
Conference Proceeding (94) 94
Book / eBook (21) 21
Book Chapter (21) 21
Book Review (8) 8
Report (5) 5
Video Recording (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
physics (1123) 1123
electricity (1066) 1066
chemistry (1021) 1021
metallurgy (1014) 1014
performing operations (887) 887
transporting (887) 887
human necessities (637) 637
humans (535) 535
heating (439) 439
mechanical engineering (437) 437
blasting (435) 435
lighting (435) 435
weapons (435) 435
basic electric elements (409) 409
electric communication technique (380) 380
male (380) 380
general tagging of cross-sectional technologies spanning over several sections of the ipc (364) 364
general tagging of new technological developments (364) 364
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (364) 364
index medicus (360) 360
female (345) 345
compositions based thereon (323) 323
organic macromolecular compounds (323) 323
their preparation or chemical working-up (323) 323
calculating (319) 319
computing (319) 319
counting (319) 319
organic chemistry (305) 305
hygiene (294) 294
medical or veterinary science (294) 294
middle aged (294) 294
optics (277) 277
electric digital data processing (267) 267
aged (265) 265
adult (233) 233
electric techniques not otherwise provided for (231) 231
oncology (228) 228
compositions of macromolecular compounds (218) 218
testing (218) 218
measuring (217) 217
preparations for medical, dental, or toilet purposes (209) 209
agriculture (208) 208
forestry (208) 208
animal husbandry (205) 205
fishing (205) 205
hunting (205) 205
trapping (205) 205
electric heating (204) 204
electric lighting not otherwise provided for (204) 204
semiconductor devices (204) 204
electric solid state devices not otherwise provided for (203) 203
transmission (203) 203
heterocyclic compounds (200) 200
technical subjects covered by former uspc (195) 195
animals (190) 190
vehicles in general (189) 189
technologies or applications for mitigation or adaptation againstclimate change (183) 183
machine tools (179) 179
metal-working not otherwise provided for (179) 179
engineering elements and units (178) 178
general measures for producing and maintaining effectivefunctioning of machines or installations (178) 178
thermal insulation in general (178) 178
generation (169) 169
conversion or distribution of electric power (165) 165
devices or arrangements, the optical operation of which ismodified by changing the optical properties of the medium of thedevices or arrangements for the control of the intensity,colour, phase, polarisation or direction of light, e.g.switching, gating, modulating or demodulating (162) 162
frequency-changing (162) 162
non-linear optics (162) 162
optical analogue/digital converters (162) 162
optical logic elements (162) 162
techniques or procedures for the operation thereof (162) 162
fixed constructions (158) 158
specific therapeutic activity of chemical compounds ormedicinal preparations (150) 150
optical elements, systems, or apparatus (148) 148
cinematography (145) 145
electrography (145) 145
holography (145) 145
photography (145) 145
cladding or plating by soldering or welding (124) 124
cutting by applying heat locally, e.g. flame cutting (124) 124
soldering or unsoldering (124) 124
welding (124) 124
working by laser beam (124) 124
investigating or analysing materials by determining theirchemical or physical properties (123) 123
cancer (120) 120
use of inorganic or non-macromolecular organic substances ascompounding ingredients (120) 120
information storage (116) 116
technical subjects covered by former us classification (114) 114
japan (109) 109
treatment outcome (107) 107
information storage based on relative movement between recordcarrier and transducer (105) 105
biocides, e.g. as disinfectants, as pesticides, as herbicides (101) 101
pest repellants or attractants (101) 101
plant growth regulators (101) 101
preservation of bodies of humans or animals or plants or partsthereof (101) 101
combustion engines (99) 99
hot-gas or combustion-product engine plants (99) 99
ferrous or non-ferrous alloys (98) 98
pictorial communication, e.g. television (98) 98
treatment of alloys or non-ferrous metals (98) 98
transmission of digital information, e.g. telegraphiccommunication (97) 97
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
UTL at Downsview - May be requested (13) 13
East Asian (Cheng Yu Tung) - Stacks (4) 4
East Asian (Cheng Yu Tung) - Reference (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Media Commons - Audio Visual (1) 1
Media Commons - Library or classroom use (1) 1
Robarts - Gov Pub Storage: Request at Reference Desk 4th floor (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6202) 6202
Japanese (627) 627
French (512) 512
German (462) 462
Chinese (142) 142
Korean (37) 37
Portuguese (25) 25
Spanish (20) 20
Norwegian (9) 9
Italian (8) 8
Danish (4) 4
Hungarian (3) 3
Slovenian (2) 2
Croatian (1) 1
Greek (1) 1
Polish (1) 1
Russian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1992, ISBN 9784062060776, 231
Book
Annals of oncology, ISSN 0923-7534, 11/2015, Volume 26, p. vii16
Journal Article
Journal Article
Cancer science, ISSN 1347-9032, 2018, Volume 109, Issue 11, pp. 3583 - 3590
Thyroid dysfunction (TD) induced by immune checkpoint inhibitors is not sufficiently understood. The purpose of this retrospective observational study was to... 
antithyroglobulin antibody | immune‐related adverse event | antithyroid peroxidase antibody | nivolumab | thyroid dysfunction | immune-related adverse event | MULTICENTER | EFFICACY | SAFETY | OPEN-LABEL | CHEMOTHERAPY | PEMBROLIZUMAB | ONCOLOGY | ADVANCED MELANOMA | JAPANESE PATIENTS | ADVERSE EVENTS | IPILIMUMAB | Hypothyroidism - chemically induced | Japan - epidemiology | Autoantibodies - metabolism | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Hypothyroidism - immunology | Young Adult | Aged, 80 and over | Adult | Female | Hypothyroidism - epidemiology | Retrospective Studies | Thyroid Gland - immunology | Thyrotoxicosis - epidemiology | Odds Ratio | Thyroid Diseases - chemically induced | Thyrotoxicosis - chemically induced | Thyrotropin - metabolism | Thyrotoxicosis - immunology | Nivolumab | Adolescent | Thyroid Diseases - epidemiology | Aged | Thyroid Diseases - immunology | Thyroid Gland - metabolism | Autoimmunity | Viral antibodies | Analysis | Antibodies | Thyrotropin | Thyroid gland | Thyroid hormones | Hypothyroidism | Risk factors | Laboratories | Menopause | Melanoma | Multivariate analysis | Patients | Skin cancer | Thyrotoxicosis | Studies | Thyroid-stimulating hormone | Immune checkpoint | Thyroxine | Peroxidase | Triiodothyronine | Clinical medicine | Solid tumors | Apoptosis | Thyroid | Pharmaceuticals | Tumors | Original
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
Cancer Science, ISSN 1347-9032, 06/2016, Volume 107, Issue 6, pp. 755 - 763
This phase I study in Japanese patients evaluated the safety, pharmacokinetics, and preliminary efficacy of palbociclib, a highly selective and reversible oral... 
letrozole | Breast cancer | cyclin‐dependent kinase | Japanese | palbociclib | cyclin-dependent kinase | CELLS | ADVANCED BREAST-CANCER | ONCOLOGY | PROLIFERATION | PD 0332991 | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Neutrophils - cytology | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Pyridines - administration & dosage | Japan | Neoplasms - enzymology | Piperazines - therapeutic use | Piperazines - adverse effects | Neoplasms - drug therapy | Survival Analysis | Aged | Neoplasms - pathology | Medical research | Chemotherapy | Estrogen | Colorectal cancer | Clinical trials | Medicine, Experimental | Dosage and administration | Postmenopausal women | Cancer | Research funding | Menopause | Metastasis | Radiation therapy | Cancer therapies | Patients | Post-menopause | Esophagus | Epidermal growth factor | Womens health | Rectum | Cell cycle | Solid tumors | Pharmacokinetics | Neutropenia | Tumors | Original
Journal Article
Journal Article
1986, Shohan., Yamamoto Noboru chosakushū, Volume 7, iv, 395, iv
Book
1984, Shohan., Yamamoto Noboru chosakushū, Volume 1, iv, 356, vii
Book
1985, Shohan., Yamamoto Noboru chosakushū, Volume 4, iii, 348, v
Book
1984, Shohan., Yamamoto Noboru chosakushū, Volume 6, 486, vii
Book
Journal Article
Cancer science, ISSN 1347-9032, 2018, Volume 109, Issue 10, pp. 3216 - 3223
Journal Article
Journal Article